Astrazeneca (AZN) Debt to Equity (2016 - 2025)
Astrazeneca has reported Debt to Equity over the past 11 years, most recently at $0.57 for Q4 2025.
- Quarterly results put Debt to Equity at $0.57 for Q4 2025, down 19.09% from a year ago — trailing twelve months through Dec 2025 was $0.57 (down 19.09% YoY), and the annual figure for FY2025 was $0.57, down 19.09%.
- Debt to Equity for Q4 2025 was $0.57 at Astrazeneca, down from $0.71 in the prior quarter.
- Over the last five years, Debt to Equity for AZN hit a ceiling of $0.76 in Q4 2022 and a floor of $0.57 in Q4 2025.
- Median Debt to Equity over the past 5 years was $0.71 (2024), compared with a mean of $0.7.
- Biggest five-year swings in Debt to Equity: tumbled 39.8% in 2021 and later grew 0.62% in 2022.
- Astrazeneca's Debt to Equity stood at $0.76 in 2021, then increased by 0.62% to $0.76 in 2022, then dropped by 8.01% to $0.7 in 2023, then increased by 0.53% to $0.71 in 2024, then decreased by 19.09% to $0.57 in 2025.
- The last three reported values for Debt to Equity were $0.57 (Q4 2025), $0.71 (Q4 2024), and $0.7 (Q4 2023) per Business Quant data.